Ogilvy NZ’s Post

Driven by the desire to continuously advance cancer diagnostics, we are committed to empowering pathologists and lab technicians worldwide to enhance efficiency and achieve high-quality results. Because when it comes to cancer, there's no time to wait. Learn more about our story: https://lnkd.in/equfCu-X #EmpoweringPathology #Pathologist

New Method Shows Promise Towards Targeting Glioblastoma https://lnkd.in/e94X5pQN

Especially for people in my network that have national marketing responsibility in the field of Oncology.

Want to learn how comprehensive genomic profiling can potentially match you to a targeted therapy for your cancer? Watch our most recent patient information webinar to learn how. The webinar will help: • To gain an understanding of precision oncology and comprehensive genomic profiling (CGP) • Provide you with details on who CGP is for and what it can offer • Give you guidance on what it involves •You'll also hear from someone who has experienced comprehensive genomic profiling first hand View patient information webinar here: https://lnkd.in/gpA-GBgF #Webinar #PatientInformationWebinar #CGP #Omico

Did you know that you can imprint more than just your company's name on promotional products? Check out our newest blog post to learn how a group of race organizers imprinted their program's name along with a hashtag to encourage social media engagement. https://lnkd.in/eJdcbjyZ #promotionalproducts #promotionalitems #promotionalgifts

Simple and highly specific microglia-targeting strategy with AAV

Introducing NCM Cares: Support Families Battling Cancer with Every Purchase We’re thrilled to announce NCM Cares, a unique Revenue Share Program that allows YOU to make a difference in the lives of families and individuals affected by cancer. With every purchase from our store, a portion of the revenue goes directly into a fund that’s shared equally among families facing the challenges of cancer. By shopping with us, you’re helping provide critical financial relief to those in need while supporting their fight against all types of cancer. How It Works: Shop from our wide range of products—supplements, blankets, and more! A portion of each sale is added to the NCM Cares Revenue Pool. The funds are distributed equally among families affected by cancer, giving them the support they deserve. Want to help? Share the pages below to help ease the financial burden on families across the country. Shop Now https://lnkd.in/gaHTQzr5 Learn More About NCM Cares https://lnkd.in/gbV3NFKg #NCMCares #RevenueShareProgram #CancerSupport #SupportFamilies #CancerAwareness #livingwithcancer #ShopForACause #Cancer #PancreaticCancer #livercancer #breastcancer #lungcancer #bonecancer #skincancer #NorthChicagoMedia

Syntara Ltd (ASX:SNT) CEO Gary Phillips joins Proactive’s Jonathan Jackson to share insights on the company's expansion of its lead drug, SNT-5505, into new medical indications, including a promising Phase 2 study targeting myelodysplastic syndrome (MDS). Phillips highlighted the significance of SNT-5505 in addressing MDS, a complex condition, underscoring the drug's potential impact on patient care. The company is collaborating with several partners in a strategic move that fosters local partnerships to advance the research. From a commercial standpoint, this development represents a pivotal advancement for Syntara, as it embarks on its fourth concurrent Phase 2 study, balancing the demands of cash flow and timelines effectively. Watch at #Proactive #ProactiveInvestors #ASX #SNT #Biotech #Biopharmaceuticals #Oncology #BloodCancer https://lnkd.in/eupG_aR4

The recent Montefiore Einstein campaign from Alto New York is storytelling at it’s best! In a world where digital trends come and go, one thing remains constant: the power of storytelling. The most successful campaigns go beyond selling products—they tell stories that resonate, connect emotionally, and drive action. Why is storytelling so effective in advertising? It’s in our DNA: We are wired to process stories, not data. Stories activate parts of our brain that evoke real-life experiences, creating a deeper connection with the message. Empathy drives action: Emotional storytelling fosters empathy and trust, building stronger relationships with audiences. It builds brand identity: Whether you’re Nike or a small business, a compelling brand story creates loyalty and sets you apart from the competition. With the growth of AI and synthetic content my only hope is that we don’t lose sight of the value of human stories. #Storytelling #Advertising #BrandIdentity

I am excited to share our recent publication where we investigated the binding affinities of fourteen ligands from BYL719 (a PI3Kα inhibitor previously discovered at Novartis) analogs. PI3Kα is a lipid kinase that is well-known as an oncogenic target in HR+/HER2- advanced breast cancer treatment. Our study employed a variety of in-silico techniques, including AMBER TI, MMPBSA, MMGBSA, docking, and machine learning, to characterize these ligands and predict their binding affinities. The structural insights from our simulations suggest that although the ligand-hinge interaction is the primary driver of ligand stability at the pocket, the R group positioning at C2 or C6 of pyridine/pyrimidine also plays a significant role. Binding affinities predicted via TI were in good agreement with previously reported affinities. However, computationally demanding techniques such as TI might not always be the most efficient approach for affinity prediction, as in our case study fast high-throughput techniques were capable of classifying compounds as active or inactive, and one docking approach showed comparable accuracy to TI. Camilo Velez Vega Cihan Soylu #cancerresearch #drugdiscovery #computationalchemistry #novartis #drugdesign